Evidence map›Paper›PMID 24946156›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2015

Evidence synthesis and guideline development in genomic medicine: current status and future prospects.

Sheri D Schully, Tram Kim Lam, W David Dotson, Christine Q Chang, Naomi Aronson, Marian L Birkeland, Stephanie Jo Brewster, Stefania Boccia, Adam H Buchanan, Ned Calonge and 16 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. From public health genomics to precision public health: a 20-year journey.Genetics in medicine : official journal of the American College of Medical Genetics · 2018
    Review
  4. Article
  5. Article
  6. Review
  7. Stakeholder engagement in policy development: challenges and opportunities for human genomics.Genetics in medicine : official journal of the American College of Medical Genetics · 2015
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sheri D SchullyEpidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
Tram Kim LamEpidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
W David DotsonOffice of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Christine Q ChangEpidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA.
Naomi AronsonTechnology Evaluation Center, Blue Cross Blue Shield Association, Chicago, Illinois, USA.
Marian L BirkelandNational Comprehensive Cancer Network, Fort Washington, Pennsylvania, USA.
Stephanie Jo BrewsterBoston Children's Hospital, Boston, Massachusetts, USA.
Stefania BocciaInstitute of Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore, Rome, Italy.
Adam H BuchananDuke Cancer Institute, Durham, North Carolina, USA.
Ned CalongeThe Colorado Trust, Denver, Colorado, USA.
Kathleen CalzoneGenetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Benjamin Djulbegovic1] University of South Florida, Tampa, Florida, USA [2] H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Katrina A B GoddardKaiser Permanente Northwest, Portland, Oregon, USA.
Roger D KleinDepartment of Molecular Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
Teri E KleinDepartment of Genetics, Stanford University, Palo Alto,California, USA.
Joseph LauBrown University, Providence, Rhode Island, USA.
Rochelle LongNational Institute of General Medical Sciences, National Institutes of Health, Bethesda, Maryland, USA.
Gary H LymanFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Rebecca L MorganDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Christina G S PalmerUniversity of California, Los Angeles, Los Angeles, California, USA.
Mary V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Wendy S RubinsteinNational Center for Biotechnology Information, National Institutes of Health, Bethesda, Maryland, USA.
Jesse J SwenLeiden University Medical Center, Leiden, The Netherlands.
Sharon F TerryGenetic Alliance, Washington, D.C., USA.
Marc S WilliamsGenomic Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA.
Muin J Khoury1] Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA [2] Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Funding

PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
NHLBI NIH HHS U01 HL105198NHLBI NIH HHS U01HL 105198NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24GM61374NIGMS NIH HHS U01 GM092666NIGMS NIH HHS U01GM 92666
6 · The paper itself

Abstract

purposeWith the accelerated implementation of genomic medicine, health-care providers will depend heavily on professional guidelines and recommendations. Because genomics affects many diseases across the life span, no single professional group covers the entirety of this rapidly developing field.

methodsTo pursue a discussion of the minimal elements needed to develop evidence-based guidelines in genomics, the Centers for Disease Control and Prevention and the National Cancer Institute jointly held a workshop to engage representatives from 35 organizations with interest in genomics (13 of which make recommendations). The workshop explored methods used in evidence synthesis and guideline development and initiated a dialogue to compare these methods and to assess whether they are consistent with the Institute of Medicine report "Clinical Practice Guidelines We Can Trust."

resultsThe participating organizations that develop guidelines or recommendations all had policies to manage guideline development and group membership, and processes to address conflicts of interests. However, there was wide variation in the reliance on external reviews, regular updating of recommendations, and use of systematic reviews to assess the strength of scientific evidence.

conclusionOngoing efforts are required to establish criteria for guideline development in genomic medicine as proposed by the Institute of Medicine.

Indexed as

Evidence-Based MedicineGenomicsPractice Guidelines as TopicHumans

Identifiers

PMID24946156
PMCPMC4272332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.